The Administrator of Drug and Controlled Substances Affairs of the Food and Drug Organization Visited Pars Isotope Company.
Utilizing radiopharmaceuticals made by Pars Isotope Co. for the feasibility and investigation of the therapeutic potential of (Ga-68/Lu-177)-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.
